ArticleFrontiers in oncology2026
STAT3 inhibitor in oncology: a trial-based analysis of translational challenges and evolving therapeutic paradigms.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Signal Transducer and Activator of Transcription 3 (STAT3), a key oncogenic target, faces clinical development hurdles for its inhibitors. A systematic retrospective analysis of Trialtrove database search yielded 130 eligible oncology trials, this perspective reveals critical developmental patterns: Trial numbers peaked in 2018 but declined post-2019, reflecting Phase III attrition due to efficacy-safety imbalances and enrollment challenges. The evolving landscape demonstrates a paradigm shift from conventional Src homology 2 (SH2) domain inhibitors toward next-generation strategies targeting the coiled-coil domain, mitochondrial STAT3, and biomarker-guided patient stratification. Realizing STAT3's therapeutic potential requires biomarker-guided patient selection, innovative inhibitors for enhanced specificity, and optimized trial strategies to bridge preclinical-clinical gaps. Learning from past outcomes and prioritizing predictive biomarkers are critical for advancing STAT3-targeted cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.